Data / Form D filings / Solve Therapeutics, Inc.
Solve Therapeutics, Inc.: Form D filings
Solve Therapeutics, Inc., a biotechnology company in Belmont, CA, filed 3 Form D notices with the SEC between 2022 and 2025. The latest, on November 25, 2025, reports $48.2 million sold of a $120.5 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1025 ALAMEDA DE LAS PULGAS, SUITE 122, Belmont, CA, 94002
- Phone
- (858) 357-4137
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1905252
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | New notice | $120,535,618 | $48,214,232 | $72,321,386 | 16 | Nov 14, 2025 | sec.gov |
| Dec 26, 2024 | New notice | $75,582,822 | $50,388,557 | $25,194,265 | 10 | Dec 13, 2024 | sec.gov |
| Jan 21, 2022 | New notice | $126,510,820 | $63,510,835 | $62,999,985 | 11 | Dec 17, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Daniel D. McHugh | Director | |
| Langdon Miller | Executive Officer | |
| David Johnson | Executive Officer, Director | |
| Clayton D. Knox | Executive Officer | |
| Robert D. Mittendorff | Director | |
| Alan Colowick | Director | |
| Jason Pitts | Director | |
| Peter Colabuono | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Nov 24, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Solve Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.